Sage China 賢者中國
The Sage Group, Inc. offers a full service for Chinese companies wishing to partner their assets in the Rest of World, especially USA and Europe, and for Western companies wishing to partner their assets with the rich corporate pharma community in the People’s Republic of China. The principal objective is to broaden Sage's strategic licensing, M&A and partnering capabilities for our healthcare clients in pharmaceuticals, biopharmaceuticals, biotechnology, diagnostics and medical technology. This will build upon Sage’s 28+ years of experience in such transactions.
The Sage Group now offers clients a full strategic advisory service with our team in China including:
Assisting our Chinese client companies with out-licensing their assets into global markets with a focus on North America and Europe
Assisting our clients in the West with licensing their pharma, diagnostic and medtech assets into the dynamic healthcare market in the Republic of China
This initiative follows on from increasing demand from our Western and Chinese clients for assistance in conducting cross-border strategic transaction initiatives to assist them in licensing and divesting their assets, and also our clients seeking new assets for in-licensing into North America, Europe and China.
Sage has conducted successfully a range of transactions with both Western and Chinese clients. One recent 2022 deal with an infectious disease asset for our Chinese client realised a very significant transaction with a top 10 global pharma company.
For a confidential discussion in more detail, please emails us China@sagehealthcare.com.
For more information about The Sage Group and opportunities for collaboration with Sage China services, please visit our website, www.sagehealthcare.com, or contact:
US Corporate Office
The Sage Group Inc.
24 E. Main Street, Box 5365
Clinton, NJ 08809 USA
Attn: Wayne Pambianchi
Phone: +1 908 230 6170
EU Corporate Office
Sage Healthcare Ltd.
Creake Road, Syderstone PE31 8SG UK
Attn: Dr. Bill Mason
Mob: +44 7785 950134